Patents

Sen. Thom Tillis
First Opinion

Proposed patent legislation would block research, stifle innovation, and harm patients

By Othman Laraki

Alex Brandon/AP
Pharmalot

FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed

By Ed Silverman

JOHNSON & JOHNSON HEADQUARTERS
Pharmalot

Baltimore sues a J&J unit over ‘sham’ patent litigation to extend its monopoly on a cancer drug

By Ed Silverman

Pharmalot

Pharmalittle: Surprise FDA approval may dampen storm over pricey drug; should the U.S. adopt reference pricing?

By Ed Silverman

Pharmalot

Pharmalittle: NAFTA deal may hinge on patent protections for drugs; House committee goes after Sacklers

By Ed Silverman

Pharmalot

Pharmalittle: Allergan depression drug fails three trials; Vertex CEO appears before Parliament

By Ed Silverman

Bristol-Myers Squibb
Pharmalot

Bristol-Myers faces growing opposition to its Celgene deal. Here’s what the wags are saying

By Ed Silverman

Colorful book shelf
First Opinion

We need a Public Domain Day to highlight when drugs go off patent

By Peter Kolchinsky and Jessica Sagers

Humira
Pharmalot

AbbVie must fork over Humira documents after judge slams a ‘nonsense’ argument

By Ed Silverman

Len Schleifer
Pharma

Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

By Ed Silverman and Matthew Herper

Pharmalot

Pharmalittle: Drug makers to raise prices in January; Novartis names a new oncology chief, again

By Ed Silverman

Drug costs
Pharmalot

Trump administration report would preclude reclaiming patents as a way to lower drug prices

By Ed Silverman

Pharmalot

Pharmalittle: Retail drug spending in the U.S. fell last year; Democrats eye patents to lower drug prices

By Ed Silverman

Pharmalot

Supreme Court to decide a patent case with big implications for small drug makers

By Ed Silverman

Pharmalot

Pharmalittle: AbbVie cancer program’s setback; Amazon hires a pharmacy expert

By Ed Silverman

German Pharma
Pharmalot

Boehringer Ingelheim abandons biosimilar sales outside the U.S.

By Ed Silverman

Pharmalot

Pharmalittle: D.C. law firms prep pharma for a Democratic house; Allergan loses another battle over Restasis patent deal

By Ed Silverman

Pharmalot

Pharmalittle: Trump hiring restrictions hurt FDA; Purdue family member has patent for addiction treatment

By Ed Silverman

Tuberculosis patient
Pharmalot

U.N. global declaration on TB passes key hurdle as U.S. and others reach a compromise

By Ed Silverman

Pharmalot

Allergan is urged to split CEO and chairman jobs by ‘disappointed’ hedge funds

By Ed Silverman

Pharmalot

Pharmalittle: Amgen migraine drug costs less than expected; J&J halts development on Alzheimer’s drug

By Ed Silverman

Pharmalot

With a push from pharma, U.S. Trade Rep pressure on Colombia starts to take hold

By Ed Silverman

Gilead Sciences
Pharmalot

Will this experimental hepatitis C treatment break Gilead’s grip on middle-income countries?

By Ed Silverman

NIH headquarters
Pharmalot

NIH is urged to probe Aegerion patents for failing to disclose federal funding

By Ed Silverman

Hepatitis C
Pharmalot

Tens of millions of people continue to lack access to hepatitis C medicines

By Ed Silverman

Gilead Sciences
Pharmalot

HHS is urged to investigate a Gilead hepatitis C patent for failing to disclose federal funding

By Ed Silverman

Anthony Anex/Keystone via AP
Pharmalot

Advocates protest Novartis ‘bullying tactics’ over access to medicines in poor countries

By Ed Silverman

Pharmalot

Pharmalittle: Will Jeff Sessions really go after opioid makers? Mylan pursues a biosimilar Botox

By Ed Silverman

Andrei Iancu - Swearing In
Pharma

The power of a patent: Will a new Trump appointee chip away at pharma’s monopolies?

By Erin Mershon

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy